key: cord-1024252-evdxxaxw
authors: Tauzin, Alexandra; Gong, Shang Yu; Beaudoin-Bussières, Guillaume; Vézina, Dani; Gasser, Romain; Nault, Lauriane; Marchitto, Lorie; Benlarbi, Mehdi; Chatterjee, Debashree; Nayrac, Manon; Laumaea, Annemarie; Prévost, Jérémie; Boutin, Marianne; Sannier, Gérémy; Nicolas, Alexandre; Bourassa, Catherine; Gendron-Lepage, Gabrielle; Medjahed, Halima; Goyette, Guillaume; Bo, Yuxia; Perreault, Josée; Gokool, Laurie; Morrisseau, Chantal; Arlotto, Pascale; Bazin, Renée; Dubé, Mathieu; De Serres, Gaston; Brousseau, Nicholas; Richard, Jonathan; Rovito, Roberta; Côté, Marceline; Tremblay, Cécile; Marchetti, Giulia C.; Duerr, Ralf; Martel-Laferrière, Valérie; Kaufmann, Daniel E.; Finzi, Andrés
title: Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
date: 2021-12-03
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.12.004
sha: a365718d8972d718b9b42bcf1baafec02d3e5ec7
doc_id: 1024252
cord_uid: evdxxaxw

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2 naïve and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naïve individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naïve vaccines. These findings suggest that longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.

baseline, no ADCC activity was observed for the naïve group before vaccination ( Figure 3A) . 196

Plasma from the PI group maintained some levels of ADCC activity before vaccination, in 197 agreement with a longitudinal study following immune responses in convalescent donors (Anand 198 et al., 2021) . Three weeks after the first dose, ADCC activity was elicited in both groups, but was 199 significantly higher in the PI group. A decline in ADCC responses was observed in both groups 200 nine weeks after V1 (V2, i.e., 12 weeks post vaccination). The second dose strongly boosted 201 ADCC activity in the naïve group but remained stable for the PI groups. In agreement with the 202 recognition of different hCoV Spikes presented in Figure 2 , the capacity of PI to mediate ADCC 203 remained relatively stable at V4 but significantly declined for naïve individuals. We note that the 204 levels of ADCC activity were significantly higher in the PI group at all timepoints ( Figure 3A ). 205

Neutralizing activity in plasma is thought to play an important role in vaccine efficacy 206 (Jackson et al., 2020; Muruato et al., 2020; Polack et al., 2020) . Accordingly, it has been recently 207 identified as an immune-correlate of protection in the mRNA-1273 COVID-19 vaccine efficacy trial 208 (Gilbert et al., 2021) . To evaluate the vaccine neutralizing response over time, we measured the 209 capacity of plasma samples to neutralize pseudoviral particles carrying the SARS-CoV-2 S 210 D614G glycoprotein ( Figure 3B ). We did not detect a significant increase in neutralization in 211 plasma isolated three weeks post vaccination of the naïve group, as previously described (Tauzin 212 et al., 2021) . Interestingly, nine weeks later (V2, i.e., 12 weeks post vaccination), we observed 213 increased neutralizing activity in a few donors ( Figure 3B ). All donors presented a significant 214 increase in neutralizing activity three weeks after the second dose. Importantly, the level of 215 neutralizing activity of double vaccinated naïve individuals reached the same levels than in the PI 216 group after one or two doses. In this latter group (PI), we measured low neutralizing activity before 217 J o u r n a l P r e -p r o o f vaccination, consistent with remaining neutralizing activity in convalescent donors after several 218 months post symptoms onset Gaebler et al., 2021; . As 219 previously described, the first dose strongly increased neutralization activity (Stamatatos et al., 220 2021; , but this activity significantly decreased a few weeks after (V2, i.e., 12 221 weeks post vaccination). The second dose boosted the neutralizing activity to the levels reached 222 three weeks after the first dose. No difference in neutralization was observed between V1 and V3 223 for PI individuals. In contrast, in naïve individuals we observed a significantly higher neutralizing 224 activity after the second dose compared to the first one ( Figure 3B ). Thus, while one dose is 225 required to reach maximum neutralization activity in PI individuals, this activity decays over time 226 and a second dose is required to bring back its maximum potential. On the other hand, naïve 227 individuals requires both doses to achieve the same level of PI vaccinated individuals three weeks 228 after the second dose. However, the neutralizing activity declined more rapidly in the naïve group 229 compared to PI individuals. Again, we observed no differences between PI that received one or 230 two doses. 231 232 Neutralizing activity against variants of concern 233 SARS-CoV-2 is evolving, and variants of concern are emerging globally (Davies et We also noted that, with the exception of B.1.1.7, plasma from the PI group prior to 243 vaccination (V0) neutralized less efficiently all pseudoviral particles bearing variant Spikes 244 compared to the D614G ( Figure S3A ). Importantly, both doses boosted the neutralizing activity 245 against all variants and SARS-CoV-1 Spike at V3 ( Figure S2D ). As observed with the D614G S, 246 the neutralizing activity decreased at V4 for all VOCs tested ( Figure S3E ). 247 Vaccination of PI individuals was shown to increase neutralization against pseudoviral 248 particles bearing the SARS-CoV-1 Spike (Stamatatos et al., 2021; . This Spike 249 is used as a representative variant that is even more dissimilar to the vaccine, which was based 250 on the ancestral Wuhan strain. While only one dose was sufficient to provide SARS-CoV-1 251 neutralizing capacity in PI individuals, two were required in naïve individuals. Three weeks after 252 the second dose (V3), plasma from naïve individuals reached the same level of neutralizing 253 activity against pseudoviral particles bearing the SARS-CoV-1 Spike than PI. Thus, suggesting 254 that the delayed boosting in naïve individuals allows antibody maturation resulting in enhanced 255 breath ( Figure S3 ). 256

To gather evidence of vaccine-elicited antibodies maturation over time, we longitudinally followed 259 RBD avidity. Briefly, we modified our ELISA assay by adding a chaotropic agent (8 M urea) to the 260 washing buffer, as reported (Björkman et al., 1999; Fialová et al., 2017; Wang et al., 2019) . By 261 performing the ELISA assay in parallel, with washing steps having or not urea (see STAR Methods 262 for details), we established an RBD avidity index (Figures 4 and S4) , which provides an overall 263 idea of the accumulated strength of vaccine-elicited antibodies affinities over time (Rudnick and 264 Adams, 2009). For PI individuals, we observed that the first dose significantly increased the RBD 265 avidity index. The second dose did not further improve the avidity. We observed no significant 266 differences between PI donors who received one or two doses at V3 and V4. No RBD avidity 267 J o u r n a l P r e -p r o o f index could be established at V0 for naïve individuals since they don't have anti-RBD antibodies. 268

However, the first dose elicited anti-RBD antibodies with a low RBD avidity index as compared to 269 the PI group. Remarkably, the second dose increased RBD avidity to the same level than for PI 270 individuals at V3 and remained relatively constant over time (V4, Figure 4) individuals that received the two doses 16 weeks apart( Figure 1A and 5A). Naïve individuals that 279 received the long interval regimen had more anti-RBD IgG ( Figure 5B ) and presented a 280 significantly higher RBD-avidity index ( Figure 5C ) than naïve donors who received their two doses 281 4 weeks apart. We also observed major differences related to their capacity to recognize the full 282

Spike of different variants. Plasma from short interval vaccinated individuals was significantly less 283 efficient at recognizing the D614G S and all other S variants tested, except for the B.1.526 S 284 ( Figure 5D ). Their capacity to mediate ADCC was also lower, albeit didn't reach statistical 285 significance ( Figure 5E ). Remarkably, the neutralization of pseudoviral particles bearing D614G 286 or almost all the variant Spike tested was significantly lower for individuals that received the two 287 doses with a short interval ( Figure 5F ). No neutralizing activity against SARS-CoV-1 was 288 observed after a short interval ( Figure 5F ). In contrast, plasmas from naïve individual who 289 received their two doses sixteen weeks apart presented a strong neutralizing activity against all 290 the SARS-CoV-2 variants but also the SARS-CoV-1 pseudoviruses ( Figure 5F ). We observed that in the SARS-CoV-2 naïve group the BNT162b2 mRNA vaccine elicited 322 antibodies with weak avidity for the RBD and neutralizing activity but strong Fc-mediated functions 323 three weeks after the first dose . These functional responses declined in the 324 following weeks in the absence of a boost. This is consistent with an overall decline in the anti-325 RBD and anti-Spike antibodies before the delayed boost. However, our results support antibody 326 maturation during this same period with a significant increase in RBD avidity. Administration of 327 the second dose sixteen weeks later strongly enhanced antibody levels but also functional 328 responses, notably neutralization against some VOCs/VOIs and even the divergent SARS-CoV-329 1. Therefore, despite initial concerns, the long interval between the doses did not result in poor 330 immune responses, A limitation of our study is the relatively low number of individuals analyzed 331 however, we note that our results are in agreement with recent findings ( To end this pandemic, it will be necessary to rapidly vaccinate the world's population, 386 including in countries where vaccines are poorly available. The research community around the 387 globe rapidly generated a wealth of data related to vaccine-elicited immune responses and 388 vaccine efficacy. Globally, these results suggest that the current vaccine strategy that was initially 389 deployed could be improved. Our results suggest that modifying the interval at which the two 390 doses are administered might be an important factor to take into account. It will be important to 391 keep in mind that a fine balance needs to be achieved in order to avoid infection between the two 392 doses and at the same time provide sufficient time to elicit optimal humoral responses. 

Household transmission of COVID-19 cases 770 associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study

High-throughput detection of antibodies targeting the 774 SARS-CoV-2 Spike in longitudinal convalescent plasma samples (Microbiology)

Longitudinal analysis of humoral 777 immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-778 symptom onset

Emergence and expansion of SARS-CoV-2

1.526 after identification in New York

Efficacy and Safety of the mRNA

CoV-2 Vaccine

Decline of Humoral Responses 787 against SARS-CoV-2 Spike in Convalescent Individuals

An anti-SARS-CoV-2 non-neutralizing antibody 790 with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-791 hACE2 mice (Microbiology)

Discriminate between Recent and Chronic Neospora Caninum Infection

Comparative Household Secondary Attack Rates associated with B.1.1.7, B.1.351, and P.1 797 SARS-CoV-2 Variants

Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA 802 vaccine-elicited antibodies

Interim estimates of increased transmissibility, growth rate, and reproduction 804 number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom

Immunological memory to SARS-CoV-2 assessed for up to 8 808 months after infection

Estimated transmissibility and 811 impact of SARS-CoV-2 lineage B.1.1.7 in England

An interactive web-based dashboard to track COVID-813 19 in real time

Risk of spread of new SARS-CoV-2 variants of concern in the EU/EEA -first 815 update

Safety and humoral responses to BNT162b2 mRNA vaccination 819 of SARS-CoV-2 previously infected and naive populations

Comparison of different enzyme-linked 821 immunosorbent assay methods for avidity determination of antiphospholipid antibodies

Progressive Increase in Virulence of Novel SARS-CoV-2 824 Variants in Ontario

Cross-reactive antibody immunity against SARS-CoV-2 in children and adults

Evolution of antibody immunity 830 to SARS-CoV-2

Immune Correlates Analysis of the 833 mRNA-1273 COVID-19 Vaccine Efficacy

mRNA vaccines induce durable 836 immune memory to SARS-CoV-2 and variants of concern

Distinct antibody and memory B cell 839 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

Waning Immunity after the BNT162b2 Vaccine 843 in Israel

Contribution of single mutations to selected 846 SARS-CoV-2 emerging variants spike antigenicity

CoV-2 with Endemic and Seasonal Betacoronaviruses

Differential sensitivity of bat cells to infection 852 by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza viruses

SARS-CoV-2 Cell Entry Depends on ACE2 856 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Evolutionary and structural 859 analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide

An mRNA Vaccine 863 against SARS-CoV-2 -Preliminary Report

Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary 865 dose vaccination

Isolation and characterization of cross-870 neutralizing coronavirus antibodies from COVID-19+ subjects

Germinal centre-driven maturation of B cell response to 873 SARS-CoV-2 vaccination

Structural Basis and Mode of Action for Two Broadly Neutralizing 876

Antibodies Against SARS-CoV-2 Emerging Variants of Concern

Differential effects 880 of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 881 recovered individuals

Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

Warp Speed" Needs Mind Melds, Not 887 Warped Minds

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and 890 vaccine evaluation

Preexisting and de novo humoral immunity to SARS-893

CoV-2 in humans

Rapid induction of antigen-specific CD4+ T 896 cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 897 mRNA vaccination

Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus 900 tropism

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after 903 extended-interval homologous dual vaccination in older people

Immunogenicity of standard and extended 906 dosing intervals of BNT162b2 mRNA vaccine

CMMID COVID-19 working group

Estimates of severity and transmissibility of novel SARS-909

CoV-2 variant 501Y.V2 in South Africa

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna 912 COVID-19 Vaccines Among Health Care Personnel -33

Reduced sensitivity of SARS-CoV-2 variant 916 Delta to antibody neutralization

Sensitivity of infectious SARS-CoV

and B.1.351 variants to neutralizing antibodies

Safety and Efficacy of the BNT162b2 mRNA 922 Covid-19 Vaccine

The great escape? SARS-CoV-2 variants evading neutralizing 924 responses

Cross-Sectional Evaluation of Humoral 927 Responses against SARS-CoV-2 Spike

Impact of temperature on the affinity of SARS-CoV-2 Spike 930 glycoprotein for host ACE2

Comparison of two highly-effective mRNA 933 vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

Open source & professional software for data science teams

SARS-CoV-2, SARS-CoV, and 940 MERS-COV: A comparative overview

Preliminary genomic characterisation of an emergent 943 SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Affinity and avidity in antibody-based tumor targeting

Resurgence of COVID-19 949 in Manaus, Brazil, despite high seroprevalence

COVID-19 vaccine BNT162b1 elicits human antibody 952 and T H 1 T cell responses

Topological Analysis for 954 Sequence Variability: Case Study on more than 2K SARS-CoV-2 sequences of COVID-19 955 infected 54 countries in comparison with SARS-CoV-1 and MERS-CoV

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Two-dose SARS-CoV-2 vaccine effectiveness 961 with mixed schedules and extended dosing intervals: test-negative design studies from British 962 Columbia and Quebec

mRNA vaccination boosts cross-965 variant neutralizing antibodies elicited by SARS-CoV-2 infection

Introduction of the South 967 African SARS-CoV-2 variant 501Y.V2 into the UK

Six-Month Effectiveness of BNT162B2 970 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study 971

BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Emergence and rapid spread of a new severe acute 978 respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations 979 in South Africa

Live imaging of SARS-CoV-2 infection in mice 982 reveals that neutralizing antibodies require Fc function for optimal efficacy

Two doses of the SARS-CoV-2

BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-987 2 infection

Transmission of SARS-CoV-2 Lineage B.1.1.7 in 990 England: Insights from linking epidemiological and genetic data

Neutralising antibody activity against SARS-CoV-2 VOCs 993 B.1.617.2 and B.1.351 by BNT162b2 vaccination

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B

Urea-mediated dissociation alleviate the false-positive Treponema pallidum-specific antibodies 1000 detected by ELISA

Naturally enhanced neutralizing breadth 1003 against SARS-CoV-2 one year after infection

Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine

under Emergency Use Listing

World Health Organization WHO Coronavirus (COVID-19) Dashboard